Country: তাইওয়ান
ভাষা: চীনা
সূত্র: 衛生福利部食品藥物管理署 (Ministry of Health and Welfare, Food And Drug Administration)
CINNARIZINE
嬌生股份有限公司 台北市大安區敦化南路二段319號4、5樓 (30814854)
N07CA02
錠劑
CINNARIZINE (0400000900) 25MG
瓶裝;;盒裝
製 劑
須由醫師處方使用
JANSSEN KOREA LTD. 905 SANGSHIN-RI, HYANGNAM-EUP, HWASEONG-SI, KYUNGGI-DO, KOREA KR
cinnarizine
噁心、眩暈、迷路障礙、暈動病、末梢血管循環障礙。
註銷日期: 2015/01/20; 註銷理由: 有效期限已屆; 有效日期: 2013/01/21; 英文品名: STUGERON TABLETS 25MG
已註銷
1998-01-21
Company Core Data Sheet – STUGERON, 25 March 2009, Version 002 1 JOHNSON & JOHNSON PHARMACEUTICAL RESEARCH & DEVELOPMENT, L.L.C. COMPANY CORE DATA SHEET STUGERON ® CINNARIZINE 25 MARCH 2009 CONFIDENTIALITY STATEMENT The information in this document contains trade secrets and commercial information that are privileged or confidential and may not be disclosed unless such disclosure is required by applicable law or regulations. In any event, persons to whom the information is disclosed must be informed that the information is _privileged_ or _confidential_ and may not be further disclosed by them. These restrictions on disclosure will apply equally to _all_ future information supplied to you which is indicated as _privileged_ or _confidential_ . Company Core Data Sheet – STUGERON, 25 March 2009, Version 002 2 1. NAME OF THE MEDICINAL PRODUCT STUGERON 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 25 mg cinnarizine per tablet. 75 mg cinnarizine per capsule. 75 mg cinnarizine per ml oral drops. For excipients, see Section 6.1. 3. PHARMACEUTICAL FORM Tablets. Capsules. Oral drops, suspension. 4. CLINICAL PARTICULARS 4.1. THERAPEUTIC INDICATIONS • Maintenance therapy for symptoms of labyrinthine disorders, including vertigo, dizziness, tinnitus, nystagmus, nausea and vomiting. • Prophylaxis of motion sickness. • Prophylaxis of migraine. • Maintenance therapy for symptoms of cerebrovascular origin, including dizziness, ear buzzing (tinnitus), vascular headache, unsociability and irritability disorders, loss of memory and lack of concentration. • Maintenance therapy for symptoms of peripheral circulatory disorders, including Raynaud’s phenomenon, acrocyanosis, intermittent claudication, trophic disturbances, trophic and varicose ulcers, paraesthesia, nocturnal cramps, cold extremities. 4.2. POSOLOGY AND METHOD OF ADMINISTRATION _Cerebral circulatory disorders: _ 1 tablet of 25 mg t.i.d. or 1 capsule of 75 mg daily, or 3 x 8 drops (= 3 x 24 mg) daily. _Peripheral circulatory disorders: _ Company Core Data She সম্পূর্ণ নথি পড়ুন